Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UK Cost Body Rejects Novartis AG's Breast Cancer Drug-Reuters


Wednesday, 20 Mar 2013 08:01pm EDT 

Reuters reported that Novartis AG's drug Afinitor has been rejected by Britain's health cost agency NICE due to uncertainty over its survival benefits in breast cancer. The Novartis drug is also used to treat patients with other types of cancer, including kidney and a rare type of pancreatic cancer. 

Company Quote

84.67
0.26 +0.31%
4:00pm EDT